VERAXA Biotech AG (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
At VERAXA, the company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
The approval of these measures marks a significant step for VERAXA as it seeks to enhance its corporate governance structure and financial flexibility. The increased board size allows for additional expertise, while the capital band and conditional share capital provide tools to raise capital efficiently when opportunities arise. This is particularly important for a biotech company focused on oncology, where substantial funding is often required to advance clinical trials and bring therapies to market.
According to the company, the strong shareholder turnout and approval rate indicate confidence in VERAXA’s strategic direction. The company’s pipeline, centered on its BiTAC platform, aims to address significant unmet medical needs in cancer treatment. With the newly approved measures, VERAXA is better positioned to execute its business plan, potentially including partnerships or acquisitions that could accelerate development.
For more information, visit the company’s newsroom at http://ibn.fm/VRXA.
